摘要 |
The invention provides a compound of the formula (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase: wherein A is a group R<SUP>2 </SUP>or CH<SUB>2</SUB>-R<SUP>2 </SUP>where R<SUP>2 </SUP>is a carbocyclic or heterocyclic group having from 3 to 12 ring members; B is a bond or an acyclic linker group having a linking chain length of up to 3 atoms selected from C, N, S and O; R<SUP>1 </SUP>is hydrogen or a group selected from SO<SUB>2</SUB>R<SUP>b</SUP>, SO<SUB>2</SUB>NR<SUP>7</SUP>R<SUP>8</SUP>, CONR<SUP>7</SUP>R<SUP>8</SUP>, NR<SUP>7</SUP>R<SUP>9 </SUP>and carbocyclic and heterocyclic groups having from 3 to 7 ring members; R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5 </SUP>and R<SUP>6 </SUP>are the same or different and are each selected from hydrogen, halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R<SUP>a</SUP>-R<SUP>b </SUP>wherein R<SUP>a </SUP>is a bond, O, CO, X<SUP>1</SUP>C(X<SUP>2</SUP>), C(X<SUP>2</SUP>)X<SUP>1</SUP>, X<SUP>1</SUP>C(X<SUP>2</SUP>)X<SUP>1</SUP>, S, SO, SO<SUB>2</SUB>, NR<SUP>c</SUP>, SO<SUB>2</SUB>NR<SUP>c </SUP>or NR<SUP>c</SUP>SO<SUB>2</SUB>; and R<SUP>b </SUP>is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C<SUB>1-8 </SUB>hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C<SUB>1-4 </SUB>hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C<SUB>1-8 </SUB>hydrocarbyl group may optionally be replaced by O, S, SO, SO<SUB>2</SUB>, NR<SUP>c</SUP>, X<SUP>1</SUP>C(X<SUP>2</SUP>), C(X<SUP>2</SUP>)X<SUP>1 </SUP>or X<SUP>1</SUP>C(X<SUP>2</SUP>)X<SUP>1</SUP>; R<SUP>c </SUP>is hydrogen or C<SUB>1-4 </SUB>hydrocarbyl; X<SUP>1 </SUP>is O, S or NR<SUP>c </SUP>and X<SUP>2 </SUP>is -O, -S or -NR<SUP>c</SUP>; R<SUP>7 </SUP>is selected from hydrogen and a C<SUB>1-8 </SUB>hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C<SUB>1-4 </SUB>hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C<SUB>1-8 </SUB>hydrocarbyl group may optionally be replaced by O, S, SO, SO<SUB>2</SUB>, NR<SUP>c</SUP>, X<SUP>1</SUP>C(X<SUP>2</SUP>), C(X<SUP>2</SUP>)X<SUP>1 </SUP>or X<SUP>1</SUP>C(X<SUP>2</SUP>)X<SUP>1</SUP>; R<SUP>8 </SUP>is selected from R<SUP>7 </SUP>and carbocyclic and heterocyclic groups having from 3 to 12 ring members; R<SUP>9 </SUP>is selected from R<SUP>8</SUP>, COR<SUP>8 </SUP>and SO<SUB>2</SUB>R<SUP>8</SUP>; or NR<SUP>7</SUP>R<SUP>8 </SUP>or NR<SUP>7</SUP>R<SUP>9 </SUP>may each form a heterocyclic group having from 5 to 12 ring members; but excluding the compounds N-[(morpholin-4-yl)phenyl-1H-indazole-3-carboxamide and N-[4-(acetylaminosulphonyl)phenyl-1H-indazole-3-carboxamide.
|